URAT1-IN-16 是一种口服活性的 URAT1 抑制剂(IC50 = 0.19 μM),同时也是 NLRP3 炎症小体通路抑制剂,可有效抑制成熟 IL-1β 的分泌(IC50 = 2.52 μM),并在体内表现出显著的降低血清尿酸和抗炎活性,可用于高尿酸血症和痛风研究。
产品编号: MS-N59099 CAS No.: 2864442-74-8 分子式: C28H23BrN4O3S2 分子量: 607.54
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

URAT1-IN-16 是一种口服活性的 URAT1 抑制剂(IC50 = 0.19 μM),同时也是 NLRP3 炎症小体通路抑制剂,可有效抑制成熟 IL-1β 的分泌(IC50 = 2.52 μM),并在体内表现出显著的降低血清尿酸和抗炎活性,可用于高尿酸血症和痛风研究。

生物实验数据

生物活性 URAT1-IN-16 is an orally active URAT1 inhibitor (IC50 = 0.19 μM) that also acts as an NLRP3 inflammasome pathway inhibitor, effectively suppressing the secretion of mature IL-1β (IC50 = 2.52 μM), and exhibits significant serum uric acid-lowering and anti-inflammatory activities in vivo, making it useful for research on hyperuricemia and gout.
IC50 & Target URAT1:0.19 μM
体外研究
(In Vitro)

URAT1-IN-16 (Compound 2) (预孵育 30 分钟;摄取实验 5 分钟) 可强效抑制 hURAT1 转染 HEK293T 细胞中的人 URAT1 介导的 14C-尿酸摄取 (IC50 = 0.19 μM)。
URAT1-IN-16 (最高浓度 10 μM;15 分钟) 在脂多糖 (LPS) 预激活并经ATP刺激的小鼠骨髓来源巨噬细胞 (BMDMs) 中剂量依赖性地抑制成熟 IL-1β 分泌和激活 Caspase-1 生成 (IC50 = 2.52 μM)。

ELISA Assay

Cell Line: BMDMs from 6-week-old male C57BL/6 WT mice were treated with LPS (1 μg/mL) and ATP (5 mM)
Concentration: Varying gradient concentrations up to 10 μM
Incubation Time: 15 min
Result: Dose-dependently inhibited mature IL-1β secretion with an IC50 value of 3.39 μM.

Western Blot Analysis

Cell Line: THP-1 cells
Concentration: 10 and 20 μM
Incubation Time: 30 min
Result: Reduced the generation of active cleaved caspase-1 in a distinct dose-dependent manner without altered levels of pro-Caspase-1, NEK7, or ASC.
体内研究
(In Vivo)

URAT1-IN-16 (Compound 2) (0.25-2 mg/kg;口服;单次给药) 可显著降低急性高尿酸血症小鼠模型中的血清尿酸 (SUA) 水平。
URAT1-IN-16 (2 mg/kg;口服;单次给药) 可显著降低高尿酸血症大鼠模型中的血清尿酸 (SUA) 水平。
URAT1-IN-16 (500-1500 mg/kg;口服;单次给药) 在健康昆明小鼠中表现出极高的急性安全性,其最大耐受剂量 (MTD) 大于 1000 mg/kg。
URAT1-IN-16 (50 mg/kg;口服;每两天一次;持续 28 天) 在健康昆明小鼠中表现出良好的亚急性耐受性,无器官毒性或体重异常变动。

Animal Model: Mouse model of acute hyperuricemia (induced by hypoxanthine and potassium oxonate)
Dosage: 0.125, 0.25, 0.5, 1, 2 mg/kg
Administration: Oral gavage (p.o.), single dose
Result: Reduced serum uric acid levels from 1162.0 μM to a normal physiological range of 143.20 μM within 4 h at 2 mg/kg, achieving a 96.8% reduction rate.
Exhibited a clear dose-dependent urate-lowering effect, with reduction rates of 93.4% (1 mg/kg), 72.6% (0.5 mg/kg), and 53.1% (0.25 mg/kg), and established a minimum effective dose of 0.25 mg/kg.
Animal Model: Rat model of hyperuricemia
Dosage: 2 mg/kg
Administration: Oral gavage (p.o.), single dose
Result: Induced a marked reduction in serum uric acid levels from 917.80 μM to 173.80 μM within 4 h post dosing, corresponding to a 91.87% decrease.
Demonstrated cross-species urate-lowering activity and showed over 3-fold superior efficacy compared with lesinurad.
Animal Model: healthy Kunming mice (10-12 g, male and female)
Dosage: 500, 1000, 1500 mg/kg
Administration: Oral gavage (p.o.), single dose
Result: Established a maximum tolerated dose (MTD) above 1000 mg/kg with 100% survival within 1 week.
Showed 80% survival at 1500 mg/kg, with two female mouse deaths occurring within 72 h at the highest dose.
Did not induce observable abnormalities in behavior, posture, appearance, or body weight gain at the MTD.
Animal Model: healthy Kunming mice (10-12 g, male and female)
Dosage: 50 mg/kg
Administration: Oral gavage (p.o.), every other day for 28 days
Result: Produced no mortality and no observable adverse behavioral effects (lethargy, convulsion, anorexia, or piloerection) during 28 days of treatment.
Maintained normal body weight gain comparable to vehicle control and showed no significant changes in major organ coefficients.
Did not induce histopathological lesions in heart, liver, spleen, lung, or kidney tissues.

化学信息

分子量 607.54
分子式 C28H23BrN4O3S2
CAS No. 2864442-74-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础